{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:09:29Z","timestamp":1792793369506,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFE0108300"],"award-info":[{"award-number":["2021YFE0108300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030049"],"award-info":[{"award-number":["82030049"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32027802"],"award-info":[{"award-number":["32027802"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11307-022-01703-7","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T20:45:47Z","timestamp":1642193147000},"page":"537-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Role of Radiomics-Based Baseline PET\/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment"],"prefix":"10.1007","volume":"24","author":[{"given":"Han","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyou","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"1703_CR1","unstructured":"Jaffe ES, Campo E (2017) Introduction and overview of the classification of lymphoid neoplasms. In: Swerdlow SH (ed) WHO classification of tumours of haematopoietic and lymphoid tissues, Edn. Revised 4th. International Agency for Research on Cancer, Lyon, France, p190\u2013198"},{"issue":"3","key":"1703_CR2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000451","volume":"26","author":"L de Leval","year":"2020","unstructured":"de Leval L, Jaffe ES (2020) Lymphoma classification. Cancer J 26(3):176\u2013185","journal-title":"Cancer J"},{"issue":"10091","key":"1703_CR3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA et al (2017) Non-Hodgkin lymphoma. Lancet 390(10091):298\u2013310","journal-title":"Lancet"},{"issue":"1","key":"1703_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors JM, Cozen W, Steidl C et al (2020) Hodgkin lymphoma. Nat Rev Dis Primers 6(1):61","journal-title":"Nat Rev Dis Primers"},{"key":"1703_CR5","unstructured":"Kaseb H, Babiker HM (2021) Hodgkin Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from:https:\/\/www.ncbi.nalm.nih.gov\/books\/NBK499969\/"},{"key":"1703_CR6","unstructured":"Sapkota S, Shaikh H. (2021) Non-Hodgkin Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559328\/?report=classic"},{"issue":"6","key":"1703_CR7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21637","volume":"70","author":"KD Miller","year":"2020","unstructured":"Miller KD, Fidler-Benaoudia M, Keegan TH et al (2020) Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin 70(6):443\u2013459","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1703_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"1703_CR9","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","volume":"136","author":"DA Eichenauer","year":"2020","unstructured":"Eichenauer DA, Engert A (2020) How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood 136(26):2987\u20132993","journal-title":"Blood"},{"issue":"1","key":"1703_CR10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","volume":"13","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR, Young KH (2020) New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol 13(1):175","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1703_CR11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","volume":"137","author":"LB Cook","year":"2021","unstructured":"Cook LB, Phillips AA (2021) How I treat adult T-cell leukemia\/lymphoma. Blood 137(4):459\u2013470","journal-title":"Blood"},{"issue":"7","key":"1703_CR12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","volume":"137","author":"CL Freeman","year":"2021","unstructured":"Freeman CL, Savage KJ, Villa DR et al (2021) Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood 137(7):929\u2013938","journal-title":"Blood"},{"key":"1703_CR13","doi-asserted-by":"crossref","unstructured":"Wright CM, Koroulakis AI, Baron JA, et al (2021) Palliative radiotherapy for diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 21(10):650\u2013658","DOI":"10.1016\/j.clml.2021.05.007"},{"issue":"1","key":"1703_CR14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-020-20488-3","volume":"12","author":"M Bunse","year":"2021","unstructured":"Bunse M, Pfeilschifter J, Bluhm J et al (2021) CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin\u2019s lymphoma and tumor-supportive follicular T helper cells. Nat Commun 12(1):240","journal-title":"Nat Commun"},{"issue":"8","key":"1703_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-021-00535-y","volume":"11","author":"SY Ong","year":"2021","unstructured":"Ong SY, de Mel S, Grigoropoulos NF et al (2021) High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J 11(8):143","journal-title":"Blood Cancer J"},{"issue":"11","key":"1703_CR16","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","volume":"3","author":"N Epperla","year":"2019","unstructured":"Epperla N, Badar T, Szabo A et al (2019) Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv 3(11):1661\u20131669","journal-title":"Blood Adv"},{"issue":"10","key":"1703_CR17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.2020007939","volume":"137","author":"NN Shah","year":"2021","unstructured":"Shah NN, Ahn KW, Litovich C et al (2021) Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? Blood 137(10):1416\u20131423","journal-title":"Blood"},{"key":"1703_CR18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2019.06.002","volume":"77","author":"JM Zaucha","year":"2019","unstructured":"Zaucha JM, Chauvie S, Zaucha R et al (2019) The role of PET\/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev 77:44\u201356","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"1703_CR19","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","volume":"136","author":"AR Hayden","year":"2020","unstructured":"Hayden AR, Tonseth P, Lee DG et al (2020) Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 136(24):2803\u20132811","journal-title":"Blood"},{"issue":"11","key":"1703_CR20","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2967\/jnumed.120.242594","volume":"61","author":"C Mesguich","year":"2020","unstructured":"Mesguich C, Bouabdallah K, Bordenave L et al (2020) Interim PET assessment of advanced Hodgkin lymphoma: is It sufficient? J Nucl Med 61(11):1694\u20131695","journal-title":"J Nucl Med"},{"issue":"1","key":"1703_CR21","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(20)30365-3","volume":"8","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Trotman J (2021) The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Haematol 8(1):e80\u2013e93","journal-title":"Lancet Haematol"},{"key":"1703_CR22","doi-asserted-by":"crossref","unstructured":"Frood R, Burton C, Tsoumpas C, et al. (2021) Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging 48(10):3198\u20133220","DOI":"10.1007\/s00259-021-05233-2"},{"issue":"4","key":"1703_CR23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.semnuclmed.2021.01.001","volume":"51","author":"HA Jacene","year":"2021","unstructured":"Jacene HA (2021) FDG PET for assessment of autologous stem cell transplantation. Semin Nucl Med 51(4):380\u2013391","journal-title":"Semin Nucl Med"},{"issue":"1","key":"1703_CR24","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1038\/s41598-021-88815-2","volume":"11","author":"YJ Park","year":"2021","unstructured":"Park YJ, Hyun SH, Moon SH et al (2021) Role in staging and prognostic value of pretherapeutic F-18 FDG PET\/CT in patients with gastric MALT lymphoma without high-grade transformation. Sci Rep 11(1):9243","journal-title":"Sci Rep"},{"issue":"1","key":"1703_CR25","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(20)30357-4","volume":"8","author":"J Trotman","year":"2021","unstructured":"Trotman J, Barrington SF (2021) The role of PET in first-line treatment of Hodgkin lymphoma. Lancet Haematol 8(1):e67\u2013e79","journal-title":"Lancet Haematol"},{"issue":"8","key":"1703_CR26","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1158\/1078-0432.CCR-04-2626","volume":"11","author":"GJ Kelloff","year":"2005","unstructured":"Kelloff GJ, Hoffman JM, Johnson B et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11(8):2785\u20132808","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1703_CR27","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1007\/s00330-018-5306-5","volume":"28","author":"S Chen","year":"2018","unstructured":"Chen S, Wang S, He K et al (2018) PET\/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients. Eur Radiol 28(7):2942\u20132950","journal-title":"Eur Radiol"},{"issue":"1","key":"1703_CR28","doi-asserted-by":"crossref","first-page":"18293","DOI":"10.1038\/s41598-021-98004-w","volume":"11","author":"A Pietrzak","year":"2021","unstructured":"Pietrzak A, Marszalek A, Kunikowska J et al (2021) Detection of clinically silent brain lesions in [18F]FDG PET\/CT study in oncological patients: analysis of over 10,000 studies. Sci Rep 11(1):18293","journal-title":"Sci Rep"},{"issue":"5","key":"1703_CR29","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/RLU.0000000000002516","volume":"44","author":"Y Abe","year":"2019","unstructured":"Abe Y, Kitadate A, Usui Y et al (2019) Diagnostic and prognostic value of using 18F-FDG PET\/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma. Clin Nucl Med 44(5):e336\u2013e341","journal-title":"Clin Nucl Med"},{"issue":"8","key":"1703_CR30","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/bloodadvances.2020001579","volume":"4","author":"R Nakajima","year":"2020","unstructured":"Nakajima R, Moskowitz AJ, Michaud L et al (2020) Baseline FDG-PET\/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Adv 4(8):1812\u20131823","journal-title":"Blood Adv"},{"issue":"9","key":"1703_CR31","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bmt.2017.143","volume":"52","author":"M Damlaj","year":"2017","unstructured":"Damlaj M, Ghazi S, Syed G et al (2017) Pre-autologous transplantation PET\/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant 52(9):1342\u20131344","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1703_CR32","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1038\/s41598-020-68310-w","volume":"10","author":"GY Song","year":"2020","unstructured":"Song GY, Yoon SE, Kim SJ et al (2020) Prognostic significance of interim PET\/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. Sci Rep 10(1):11649","journal-title":"Sci Rep"},{"issue":"3","key":"1703_CR33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C et al (2021) Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(dagger). Ann Oncol 32(3):404\u2013411","journal-title":"Ann Oncol"},{"issue":"1","key":"1703_CR34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS et al (2020) (18)F-FDG PET dissemination features in diffuse large B-cell lymphoma Are predictive of outcome. J Nucl Med 61(1):40\u201345","journal-title":"J Nucl Med"},{"issue":"3","key":"1703_CR35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s13139-017-0500-y","volume":"52","author":"JW Lee","year":"2018","unstructured":"Lee JW, Lee SM (2018) Radiomics in oncological PET\/CT: clinical applications. Nucl Med Mol Imaging 52(3):170\u2013189","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"1703_CR36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13139-019-00571-4","volume":"53","author":"S Ha","year":"2019","unstructured":"Ha S, Choi H, Paeng JC et al (2019) Radiomics in oncological PET\/CT: a methodological overview. Nucl Med Mol Imaging 53(1):14\u201329","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"1703_CR37","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1038\/s41467-020-18497-3","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu J, Deng Y, Liu T et al (2020) Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics. Nat Commun 11(1):4807","journal-title":"Nat Commun"},{"issue":"2","key":"1703_CR38","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00330-020-07141-9","volume":"31","author":"MR Chetan","year":"2021","unstructured":"Chetan MR, Gleeson FV (2021) Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. Eur Radiol 31(2):1049\u20131058","journal-title":"Eur Radiol"},{"issue":"1","key":"1703_CR39","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1038\/s41467-020-19116-x","volume":"11","author":"W Mu","year":"2020","unstructured":"Mu W, Jiang L, Zhang J et al (2020) Non-invasive decision support for NSCLC treatment using PET\/CT radiomics. Nat Commun 11(1):5228","journal-title":"Nat Commun"},{"issue":"1","key":"1703_CR40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41398-021-01586-2","volume":"11","author":"M Bang","year":"2021","unstructured":"Bang M, Eom J, An C et al (2021) An interpretable multiparametric radiomics model for the diagnosis of schizophrenia using magnetic resonance imaging of the corpus callosum. Transl Psychiatry 11(1):462","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1703_CR41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41698-021-00205-z","volume":"5","author":"J Yan","year":"2021","unstructured":"Yan J, Zhang B, Zhang S et al (2021) Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients. NPJ Precis Oncol 5(1):72","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"1703_CR42","doi-asserted-by":"crossref","first-page":"17885","DOI":"10.1038\/s41598-021-97497-9","volume":"11","author":"N Yang","year":"2021","unstructured":"Yang N, Liu F, Li C et al (2021) Diagnostic classification of coronavirus disease 2019 (COVID-19) and other pneumonias using radiomics features in CT chest images. Sci Rep 11(1):17885","journal-title":"Sci Rep"},{"issue":"1","key":"1703_CR43","doi-asserted-by":"crossref","first-page":"18347","DOI":"10.1038\/s41598-021-97796-1","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Mao Y, Chen J et al (2021) Radiomics-based model for predicting early recurrence of intrahepatic mass-forming cholangiocarcinoma after curative tumor resection. Sci Rep 11(1):18347","journal-title":"Sci Rep"},{"issue":"4","key":"1703_CR44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2967\/jnumed.118.222893","volume":"61","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Materka A, Langs G et al (2020) Introduction to radiomics. J Nucl Med 61(4):488\u2013495","journal-title":"J Nucl Med"},{"issue":"13","key":"1703_CR45","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s00259-019-04420-6","volume":"46","author":"ME Mayerhoefer","year":"2019","unstructured":"Mayerhoefer ME, Riedl CC, Kumar A et al (2019) Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging 46(13):2760\u20132769","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1703_CR46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymeth.2020.06.020","volume":"188","author":"ME Mayerhoefer","year":"2021","unstructured":"Mayerhoefer ME, Umutlu L, Schoder H (2021) Functional imaging using radiomic features in assessment of lymphoma. Methods 188:105\u2013111","journal-title":"Methods"},{"issue":"1","key":"1703_CR47","doi-asserted-by":"crossref","first-page":"10640","DOI":"10.1038\/s41598-019-46937-8","volume":"9","author":"G Reynes-Llompart","year":"2019","unstructured":"Reynes-Llompart G, Sabate-Llobera A, Llinares-Tello E et al (2019) Image quality evaluation in a modern PET system: impact of new reconstructions methods and a radiomics approach. Sci Rep 9(1):10640","journal-title":"Sci Rep"},{"issue":"8","key":"1703_CR48","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1007\/s00259-021-05234-1","volume":"48","author":"M Tian","year":"2021","unstructured":"Tian M, He X, Jin C et al (2021) Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging 48(8):2338\u20132350","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1703_CR49","doi-asserted-by":"publisher","unstructured":"Jin X, Wei M, Wang S, et al. (2021) Detecting fibroblast activation proteins in lymphoma using (68)Ga-FAPI PET\/CT. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.121.262134","DOI":"10.2967\/jnumed.121.262134"},{"issue":"6","key":"1703_CR50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MNM.0000000000001197","volume":"41","author":"J Tsuchiya","year":"2020","unstructured":"Tsuchiya J, Yoneyama T, Ohtake M et al (2020) Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET\/computed tomography in a small patient cohort. Nucl Med Commun 41(6):567\u2013574","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1703_CR51","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00259-020-04946-0","volume":"48","author":"G Wang","year":"2021","unstructured":"Wang G, Jin X, Zhu H et al (2021) (68)Ga-NOTA-FAPI-04 PET\/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [(18)F] FDG PET\/CT. Eur J Nucl Med Mol Imaging 48(2):647\u2013648","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1703_CR52","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00259-019-04323-6","volume":"46","author":"L Zanoni","year":"2019","unstructured":"Zanoni L, Broccoli A, Lambertini A et al (2019) Role of 18F-FLT PET\/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. Eur J Nucl Med Mol Imaging 46(8):1661\u20131671","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1703_CR53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41416-021-01387-w","volume":"125","author":"G Singh","year":"2021","unstructured":"Singh G, Manjila S, Sakla N et al (2021) Radiomics and radiogenomics in gliomas: a contemporary update. Br J Cancer 125(5):641\u2013657","journal-title":"Br J Cancer"},{"issue":"2","key":"1703_CR54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Vallieres M, Abdalah MA et al (2020) The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 295(2):328\u2013338","journal-title":"Radiology"},{"issue":"1","key":"1703_CR55","first-page":"72","volume":"65","author":"S Zhu","year":"2021","unstructured":"Zhu S, Xu H, Shen C et al (2021) Differential diagnostic ability of 18F-FDG PET\/CT radiomics features between renal cell carcinoma and renal lymphoma. Q J Nucl Med Mol Imaging 65(1):72\u201378","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"1","key":"1703_CR56","first-page":"135","volume":"83","author":"H Tomita","year":"2021","unstructured":"Tomita H, Yamashiro T, Iida G et al (2021) Unenhanced CT texture analysis with machine learning for differentiating between nasopharyngeal cancer and nasopharyngeal malignant lymphoma. Nagoya J Med Sci 83(1):135\u2013149","journal-title":"Nagoya J Med Sci"},{"issue":"3","key":"1703_CR57","first-page":"351","volume":"75","author":"K Mitamura","year":"2021","unstructured":"Mitamura K, Norikane T, Yamamoto Y et al (2021) Texture indices of 18F-FDG PET\/CT for differentiating squamous cell carcinoma and Non-Hodgkin\u2019s lymphoma of the oropharynx. Acta Med Okayama 75(3):351\u2013356","journal-title":"Acta Med Okayama"},{"issue":"4","key":"1703_CR58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/CM9.0000000000001206","volume":"134","author":"YW Sun","year":"2020","unstructured":"Sun YW, Ji CF, Wang H et al (2020) Differentiating gastric cancer and gastric lymphoma using texture analysis (TA) of positron emission tomography (PET). Chin Med J (Engl) 134(4):439\u2013447","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"1703_CR59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cam4.2711","volume":"9","author":"X Ou","year":"2020","unstructured":"Ou X, Zhang J, Wang J et al (2020) Radiomics based on (18) F-FDG PET\/CT could differentiate breast carcinoma from breast lymphoma using machine-learning approach: a preliminary study. Cancer Med 9(2):496\u2013506","journal-title":"Cancer Med"},{"key":"1703_CR60","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fonc.2019.00844","volume":"9","author":"H Xu","year":"2019","unstructured":"Xu H, Guo W, Cui X et al (2019) Three-dimensional texture analysis based on PET\/CT images to distinguish hepatocellular carcinoma and hepatic lymphoma. Front Oncol 9:844","journal-title":"Front Oncol"},{"key":"1703_CR61","first-page":"4507694","volume":"2019","author":"X Ou","year":"2019","unstructured":"Ou X, Wang J, Zhou R et al (2019) Ability of (18)F-FDG PET\/CT Radiomic features to distinguish breast carcinoma from breast lymphoma. Contrast media Mol imaging 2019:4507694","journal-title":"Contrast media Mol imaging"},{"key":"1703_CR62","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.nicl.2019.101912","volume":"23","author":"Z Kong","year":"2019","unstructured":"Kong Z, Jiang C, Zhu R et al (2019) (18)F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma. Neuroimage Clin 23:101912","journal-title":"Neuroimage Clin"},{"issue":"10","key":"1703_CR63","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s10147-019-01482-2","volume":"24","author":"M Tatsumi","year":"2019","unstructured":"Tatsumi M, Isohashi K, Matsunaga K et al (2019) Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol 24(10):1292\u20131300","journal-title":"Int J Clin Oncol"},{"key":"1703_CR64","doi-asserted-by":"crossref","unstructured":"Coskun N, Okudan B, Uncu D, et al. (2021) Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma. Nucl Med Commun 42(11):1227\u20131232","DOI":"10.1097\/MNM.0000000000001447"},{"key":"1703_CR65","first-page":"2981585","volume":"2020","author":"Y Sun","year":"2020","unstructured":"Sun Y, Qiao X, Jiang C et al (2020) Texture analysis improves the value of pretreatment (18)F-FDG PET\/CT in predicting interim response of primary gastrointestinal diffuse large B-cell lymphoma. Contrast Media Mol Imaging 2020:2981585","journal-title":"Contrast Media Mol Imaging"},{"issue":"5","key":"1703_CR66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00259-017-3899-6","volume":"45","author":"N Aide","year":"2018","unstructured":"Aide N, Talbot M, Fruchart C et al (2018) Diagnostic and prognostic value of baseline FDG PET\/CT skeletal textural features in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging 45(5):699\u2013711","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1703_CR67","doi-asserted-by":"crossref","unstructured":"Mayerhoefer ME, Riedl CC, Kumar A, et al. (2020) [18F]FDG-PET\/CT Radiomics for prediction of bone marrow involvement in mantle cell lymphoma: a retrospective study in 97 patients. Cancers (Basel), 12(5):1138","DOI":"10.3390\/cancers12051138"},{"issue":"6","key":"1703_CR68","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12149-018-1260-1","volume":"32","author":"A Parvez","year":"2018","unstructured":"Parvez A, Tau N, Hussey D et al (2018) (18)F-FDG PET\/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin\u2019s lymphoma as predictors of treatment outcome and survival. Ann Nucl Med 32(6):410\u2013416","journal-title":"Ann Nucl Med"},{"issue":"8","key":"1703_CR69","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.acra.2019.10.015","volume":"27","author":"KH Lue","year":"2020","unstructured":"Lue KH, Wu YF, Liu SH et al (2020) Intratumor heterogeneity assessed by (18)F-FDG PET\/CT predicts treatment response and survival outcomes in patients with Hodgkin lymphoma. Acad Radiol 27(8):e183\u2013e192","journal-title":"Acad Radiol"},{"issue":"12","key":"1703_CR70","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/RLU.0000000000001375","volume":"41","author":"KY Ko","year":"2016","unstructured":"Ko KY, Liu CJ, Ko CL et al (2016) Intratumoral heterogeneity of pretreatment 18F-FDG PET images predict disease progression in patients with nasal type extranodal natural killer\/T-cell lymphoma. Clin Nucl Med 41(12):922\u2013926","journal-title":"Clin Nucl Med"},{"issue":"10","key":"1703_CR71","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000002732","volume":"44","author":"KH Lue","year":"2019","unstructured":"Lue KH, Wu YF, Liu SH et al (2019) Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with Hodgkin lymphoma. Clin Nucl Med 44(10):e559\u2013e565","journal-title":"Clin Nucl Med"},{"key":"1703_CR72","first-page":"2641627","volume":"2019","author":"M Wang","year":"2019","unstructured":"Wang M, Xu H, Xiao L et al (2019) Prognostic value of functional parameters of (18)F-FDG-PET images in patients with primary renal\/adrenal lymphoma. Contrast Media Mol Imaging 2019:2641627","journal-title":"Contrast Media Mol Imaging"},{"key":"1703_CR73","doi-asserted-by":"crossref","first-page":"5963607","DOI":"10.1155\/2019\/5963607","volume":"2019","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Ma XL, Pu LT et al (2019) Prediction of overall survival and progression-free survival by the (18)F-FDG PET\/CT radiomic features in patients with primary gastric diffuse large B-cell lymphoma. Contrast Media Mol Imaging 2019:5963607","journal-title":"Contrast Media Mol Imaging"},{"issue":"8","key":"1703_CR74","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","volume":"30","author":"N Aide","year":"2020","unstructured":"Aide N, Fruchart C, Nganoa C et al (2020) Baseline (18)F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol 30(8):4623\u20134632","journal-title":"Eur Radiol"},{"key":"1703_CR75","doi-asserted-by":"crossref","unstructured":"Lue KH, Wu YF, Lin HH, et al. (2020) Prognostic value of baseline radiomic features of (18)F-FDG PET in patients with diffuse large B-cell lymphoma. Diagnostics (Basel) 11(1):36","DOI":"10.3390\/diagnostics11010036"},{"issue":"10","key":"1703_CR76","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1007\/s00330-020-06943-1","volume":"30","author":"H Wang","year":"2020","unstructured":"Wang H, Zhao S, Li L et al (2020) Development and validation of an (18)F-FDG PET radiomic model for prognosis prediction in patients with nasal-type extranodal natural killer\/T cell lymphoma. Eur Radiol 30(10):5578\u20135587","journal-title":"Eur Radiol"},{"issue":"1","key":"1703_CR77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40644-020-00379-y","volume":"21","author":"H Li","year":"2021","unstructured":"Li H, Shao G, Zhang Y et al (2021) Nomograms based on SUVmax of (18)F-FDG PET\/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma. Cancer Imaging 21(1):9","journal-title":"Cancer Imaging"},{"issue":"10","key":"1703_CR78","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/RLU.0000000000000539","volume":"39","author":"E Mena","year":"2014","unstructured":"Mena E, Lindenberg ML, Turkbey BI et al (2014) A pilot study of the value of 18F-fluoro-deoxy-thymidine PET\/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. Clin Nucl Med 39(10):874\u2013881","journal-title":"Clin Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T13:17:38Z","timestamp":1658236658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01703-7","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}